Vytala
1 known investors
Vytala develops a plant-based medical food using its Lym-X-Sorb lipid technology to improve absorption of dietary fat, choline, and essential fatty acids in patients with fat malabsorption from conditions such as cystic fibrosis and pancreatic insufficiency. The product aims to reduce GI symptoms and support weight, growth, and nutrient status without complex diets or medications, and is reimbursable through CMS.